MRPL48 and hepatocellular carcinoma: Furthermore, patients with MRPL48 CNV gain had a higher level of expression of MRPL48 in HCC, but only 6.8 percent of these patients (24/353 patients) showed this manifestation in MRPL48 (Fig. 4A).